<DOC>
	<DOC>NCT00772720</DOC>
	<brief_summary>Raltegravir is the first of a new antiretroviral class. A better profile of metabolic toxicity is expected. In order to better define its effects, without interference with other drugs, a study on healthy volunteers is warranted.</brief_summary>
	<brief_title>Effects of Raltegravir (IsentressÂ®) on Lipid and Carbohydrate Metabolism and Mitochondrial Function in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>1. Healthy male. 2. age between 18 and 45. 3. BMI between 19 and 25 kg/m2 4. Normal physical exam. 5. Blood analysis without relevant findings. 6. Negative serology for hepatitis B, Hepatitis C and HIV. 7. Negative urine test for abuse drugs. 1. Severe psychiatric disease. 2. Dyslipemia. 3. Alcohol intake above 30 g per day. 4. Smokers 5. Xanthine intake above 5 coffee cup equivalents per day 6. Use of any drugs in the last month 7. Participation in other trials in the last 3 months 8. Diseases capable to modify drug ADME 9. Drug allergy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2010</verification_date>
</DOC>